Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis.

Importance Compared with non-Hispanic White individuals, African American individuals from the same community are approximately twice as likely to develop Alzheimer disease. Despite this disparity, the largest Alzheimer disease genome-wide association studies to date have been conducted in non-Hispanic White individuals. In the largest association analyses of Alzheimer disease in African American individuals, ABCA7, TREM2, and an intergenic locus at 5q35 were previously implicated. Objective To identify additional risk loci in African American individuals by increasing the sample size and using the African Genome Resource panel. Design, Setting, and Participants This genome-wide association meta-analysis used case-control and family-based data sets from the Alzheimer Disease Genetics Consortium. There were multiple recruitment sites throughout the United States that included individuals with Alzheimer disease and controls of African American ancestry. Analysis began October 2018 and ended September 2019. Main Outcomes and Measures Diagnosis of Alzheimer disease. Results A total of 2784 individuals with Alzheimer disease (1944 female [69.8%]) and 5222 controls (3743 female [71.7%]) were analyzed (mean [SD] age at last evaluation, 74.2 [13.6] years). Associations with 4 novel common loci centered near the intracellular glycoprotein trafficking gene EDEM1 (3p26; P = 8.9 × 10-7), near the immune response gene ALCAM (3q13; P = 9.3 × 10-7), within GPC6 (13q31; P = 4.1 × 10-7), a gene critical for recruitment of glutamatergic receptors to the neuronal membrane, and within VRK3 (19q13.33; P = 3.5 × 10-7), a gene involved in glutamate neurotoxicity, were identified. In addition, several loci associated with rare variants, including a genome-wide significant intergenic locus near IGF1R at 15q26 (P = 1.7 × 10-9) and 6 additional loci with suggestive significance (P ≤ 5 × 10-7) such as API5 at 11p12 (P = 8.8 × 10-8) and RBFOX1 at 16p13 (P = 5.4 × 10-7) were identified. Gene expression data from brain tissue demonstrate association of ALCAM, ARAP1, GPC6, and RBFOX1 with brain β-amyloid load. Of 25 known loci associated with Alzheimer disease in non-Hispanic White individuals, only APOE, ABCA7, TREM2, BIN1, CD2AP, FERMT2, and WWOX were implicated at a nominal significance level or stronger in African American individuals. Pathway analyses strongly support the notion that immunity, lipid processing, and intracellular trafficking pathways underlying Alzheimer disease in African American individuals overlap with those observed in non-Hispanic White individuals. A new pathway emerging from these analyses is the kidney system, suggesting a novel mechanism for Alzheimer disease that needs further exploration. Conclusions and Relevance While the major pathways involved in Alzheimer disease etiology in African American individuals are similar to those in non-Hispanic White individuals, the disease-associated loci within these pathways differ.

K. Lunetta | D. Geschwind | H. Hakonarson | J. Buxbaum | M. Cuccaro | J. Haines | M. Pericak-Vance | G. Schellenberg | M. Albert | J. Morris | C. DeCarli | L. Schneider | C. Lyketsos | D. Bennett | A. Myers | R. Petersen | J. Trojanowski | D. Blacker | J. Growdon | B. Hyman | B. Reisberg | T. Grabowski | A. Saykin | P. S. St George-Hyslop | J. Becker | R. Albin | A. Levey | J. Kaye | R. Mayeux | M. Sano | B. Boeve | H. Paulson | O. Lopez | L. Apostolova | D. Galasko | J. Brewer | M. Frosch | D. Dickson | J. Parisi | R. Doody | J. Quinn | N. Cairns | B. Ghetti | J. Ringman | E. Reiman | E. Martin | J. Vance | L. Honig | D. Royall | S. Arnold | L. Farrer | H. Chui | J. Kramer | W. Seeley | K. Welsh-Bohmer | E. Bigio | S. Weintraub | J. Manly | R. Tanzi | M. Gearing | A. Goate | J. Kauwe | C. Cruchaga | M. Carrasquillo | S. Younkin | T. Obisesan | S. Strittmatter | H. Vinters | Denis A. Evans | P. D. De Jager | W. Kukull | T. Wisniewski | T. Foroud | P. Crane | V. Henderson | J. Troncoso | C. Reitz | S. Small | A. Boxer | A. Karydas | D. Marson | K. Wilhelmsen | M. Huentelman | J. Lah | K. Hall | H. Hendrie | J. Reisch | A. McDavid | T. Bird | D. Fardo | A. Naj | G. Jun | G. Beecham | B. Vardarajan | B. Kunkle | C. Baldwin | M. Kamboh | E. Larson | E. Rogaeva | D. Tsuang | O. Valladares | K. Hamilton-Nelson | K. Faber | L. Cantwell | T. Beach | Chang-En Yu | M. Fallin | G. Jarvik | J. Vonsattel | R. Rosenberg | N. Graff-Radford | S. Asthana | C. Carlsson | M. Sager | S. O'Bryant | R. Swerdlow | N. Kowall | C. Hulette | R. Woltjer | E. Roberson | S. Ferris | F. LaFerla | E. Peskind | T. Golde | N. Ertekin-Taner | W. McCormick | Ge Li | S. Craft | S. McCurry | J. Olichney | J. Burke | E. Abner | H. Klein | T. Wingo | L. Barnes | S. Barral | Amanda Kuzma | R. Duara | M. Logue | C. Atwood | R. Vassar | R. Go | M. Raskind | J. Burns | D. Cribbs | A. Lieberman | V. V. Van Deerlin | J. Leverenz | L. V. Van Eldik | R. Barber | L. Qu | M. Katz | C. Cao | R. Carney | K. Fallon | F. Martiniuk | A. Pierce | W. Poon | H. Potter | A. Raj | J. Sonnen | S. Spina | J. Williamson | G. Byrd | R. Go | David A. Bennett | Y. Leung | Yi Zhao | J. Malamon | T. Fairchild | R. Huebinger | M. Mesulam | C. Keene | L. Adams | J. Mez | Michael A. Schmidt | Jaeyoon Chung | S. Mukherjee | S. McDonough | Takiyah D. Starks | T. Montine | R. Lipton | Lee‐way Jin | L. Harrell | Hank Paulson | B. Miller | M. Albert | M. Farlow | V. W. Henderson | Paul K. Crane | Eric B. Larson | J. Schneider | J. Chung | V. V. van Deerlin | Chuang‐Kuo Wu | Ronald Kim | J. Brewer | H. Rosen | R. Swerdlow | Li-Sao Wang | Izri Martinez | Temitope Ayodele | Melissa Jean-Francois | V. Henderson | Lei Yu | John Hardy | A. Mckee | Eliezer Masliah | Melissa Jean‐Francois | P. Adams | T. Starks | B. Miller | R. Stern | J. Bowen | J. Gilbert | R. Hamilton | A. Kuzma | J. Morris | C. Miller | R. Green | Malcom Dick | M. Jean‐Francois | J. Haines | J. Morris | J. Morris | J. Schneider | Jesse B. Mez | Murray M. Raskind | E. Masliah | Victor W Henderson | M. Fallin

[1]  Sterling C. Johnson,et al.  Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. , 2020, JAMA neurology.

[2]  Joanne C. Beer,et al.  Population-based genome-wide association study of cognitive decline in older adults free of dementia: identification of a novel locus for the attention domain , 2019, Neurobiology of Aging.

[3]  C. DeCarli,et al.  Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center. , 2019, Journal of Alzheimer's Disease.

[4]  Brian A. Gordon,et al.  Assessment of Racial Disparities in Biomarkers for Alzheimer Disease , 2019, JAMA neurology.

[5]  Genetic,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[6]  Nick C Fox,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[7]  Kevin F. Bieniek,et al.  Ethnoracial differences in Alzheimer’s disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort , 2019, Alzheimer's & Dementia.

[8]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[9]  Annie W Shieh,et al.  Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder , 2018, Science.

[10]  M. Cuccaro,et al.  Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations , 2018, PLoS genetics.

[11]  Jenny I. Shen,et al.  Kidney Disease Among African Americans: A Population Perspective. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  A. Gross,et al.  Dementia, Alzheimer's Disease, and Mortality after Hemodialysis Initiation. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[13]  D. Hebert,et al.  EDEM1's mannosidase-like domain binds ERAD client proteins in a redox-sensitive manner and possesses catalytic activity , 2018, Journal of Biological Chemistry.

[14]  L. Farrer,et al.  Genome‐wide association study of cognitive flexibility assessed by the Wisconsin Card Sorting Test , 2018, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[15]  H. Najafabadi,et al.  Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer’s disease , 2017, Nature Communications.

[16]  F. McMahon,et al.  Sodium valproate rescues expression of TRANK1 in iPSC-derived neural cells that carry a genetic variant associated with serious mental illness , 2017, bioRxiv.

[17]  Nick C Fox,et al.  Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease , 2017, Nature Genetics.

[18]  D. Serie,et al.  African American exome sequencing identifies potential risk variants at Alzheimer disease loci , 2017, Neurology: Genetics.

[19]  J. Attems,et al.  Common Impact of Chronic Kidney Disease and Brain Microhemorrhages on Cerebral Aβ Pathology in SHRSP , 2017, Brain pathology.

[20]  Janice M. Fullerton,et al.  Identification of shared risk loci and pathways for bipolar disorder and schizophrenia , 2017, PloS one.

[21]  K. Lunetta,et al.  Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans , 2017, Alzheimer's & Dementia.

[22]  J. Billard,et al.  Deleting IGF-1 receptor from forebrain neurons confers neuroprotection during stroke and upregulates endocrine somatotropin , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  Sung-Hoon Kim,et al.  VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and Aβ accumulation via enhancement of ERK phosphatase VHR activity , 2016, Scientific Reports.

[24]  Lilah M. Besser,et al.  Neuropathologic differences by race from the National Alzheimer's Coordinating Center , 2016, Alzheimer's & Dementia.

[25]  Derek J Van Booven,et al.  ABCA7 frameshift deletion associated with Alzheimer disease in African Americans , 2016, Neurology: Genetics.

[26]  Timothy J. Hohman,et al.  Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk , 2016, Alzheimer's & Dementia.

[27]  D. Geschwind,et al.  Cytoplasmic Rbfox1 Regulates the Expression of Synaptic and Autism-Related Genes , 2016, Neuron.

[28]  K. Nagata,et al.  Role of the cytoplasmic isoform of RBFOX1/A2BP1 in establishing the architecture of the developing cerebral cortex , 2015, Molecular Autism.

[29]  M. Holzenberger,et al.  Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-β Clearance , 2015, The Journal of Neuroscience.

[30]  S. Leurgans,et al.  Mixed pathology is more likely in black than white decedents with Alzheimer dementia , 2015, Neurology.

[31]  S. Lincoln,et al.  TREM2 is associated with increased risk for Alzheimer’s disease in African Americans , 2015, Molecular Neurodegeneration.

[32]  Joris M. Mooij,et al.  MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..

[33]  J. Gallacher,et al.  Convergent genetic and expression data implicate immunity in Alzheimer's disease , 2014, Alzheimer's & Dementia.

[34]  Hitoshi Suzuki,et al.  Alternative splicing regulation of APP exon 7 by RBFox proteins , 2014, Neurochemistry International.

[35]  K. Lunetta,et al.  Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans , 2014, Alzheimer's & Dementia.

[36]  S. Djurovic,et al.  Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia , 2013, Molecular Psychiatry.

[37]  P. Crane,et al.  Alzheimer’s Disease: Analyzing the Missing Heritability , 2013, PloS one.

[38]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[39]  R. Mayeux,et al.  TREM2 and neurodegenerative disease. , 2013, The New England journal of medicine.

[40]  H. Prats,et al.  Api5 Contributes to E2F1 Control of the G1/S Cell Cycle Phase Transition , 2013, PloS one.

[41]  Oscar L Lopez,et al.  Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. , 2013, JAMA.

[42]  Curtis Tatsuoka,et al.  Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment , 2013, Alzheimer's Research & Therapy.

[43]  S. Cichon,et al.  Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder , 2013, Molecular Psychiatry.

[44]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[45]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[46]  S Cichon,et al.  Genome-wide association of mood-incongruent psychotic bipolar disorder , 2012, Translational Psychiatry.

[47]  Lan Jiang,et al.  Genome‐Wide Association and Linkage Study in the Amish Detects a Novel Candidate Late‐Onset Alzheimer Disease Gene , 2012, Annals of human genetics.

[48]  J. Schneider,et al.  Overview and findings from the religious orders study. , 2012, Current Alzheimer research.

[49]  Stephen J. Smith,et al.  Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors , 2012, Nature.

[50]  J. Schneider,et al.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.

[51]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[52]  P. Sham,et al.  Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases , 2011, Genetic epidemiology.

[53]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[54]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[55]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[56]  Y. Kitamura,et al.  Loss of HRD1-Mediated Protein Degradation Causes Amyloid Precursor Protein Accumulation and Amyloid-β Generation , 2010, The Journal of Neuroscience.

[57]  E. Masliah,et al.  Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice , 2010, Cell.

[58]  T. Kadowaki,et al.  Neuronal IGF‐1 resistance reduces Aβ accumulation and protects against premature death in a model of Alzheimer's disease , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[60]  D. Hebert,et al.  EDEM1 recognition and delivery of misfolded proteins to the SEL1L-containing ERAD complex. , 2009, Molecular cell.

[61]  Kyong-Tai Kim,et al.  Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase , 2006, Nature Cell Biology.

[62]  D. Small,et al.  Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. , 2006, Biochemistry.

[63]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[64]  D. Black,et al.  Molecular basis of RNA recognition by the human alternative splicing factor Fox‐1 , 2006, The EMBO journal.

[65]  R. Huganir,et al.  MAPK cascade signalling and synaptic plasticity , 2004, Nature Reviews Neuroscience.

[66]  P. Wesseling,et al.  Heparan sulphate proteoglycans in Alzheimer's disease and amyloid‐related disorders , 2003, The Lancet Neurology.

[67]  Maurizio Molinari,et al.  Role of EDEM in the Release of Misfolded Glycoproteins from the Calnexin Cycle , 2003, Science.

[68]  Martin Holzenberger,et al.  IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice , 2003, Nature.

[69]  P. Wesseling,et al.  Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques , 2002, Neurobiology of Aging.

[70]  P. Wesseling,et al.  Heparan sulfate proteoglycan expression in cerebrovascular amyloid β deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains , 2001, Acta Neuropathologica.

[71]  Karl Deisseroth,et al.  Spaced stimuli stabilize MAPK pathway activation and its effects on dendritic morphology , 2001, Nature Neuroscience.

[72]  R. Costa,et al.  Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan , 2001, Neurology.

[73]  T. Wight,et al.  Perlecan Binds to the β‐Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains Aβ Fibril Stability , 1997 .

[74]  H. Fillit,et al.  Heparin promotes ß-secretase cleavage of the Alzheimer's amyloid precursor protein , 1997, Neurochemistry International.

[75]  Alexander Meissner,et al.  Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. , 2015, JAMA neurology.

[76]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[77]  M. Albert,et al.  Results of a high-resolution genome screen of 437 Alzheimer's disease families. , 2003, Human molecular genetics.